Mr. Huang Kai, director of Jingzhou Investment Promotion Office in Guangzhou, visited Shenzhen Cell Valley
Under the careful introduction of Minister Sun Rui, Director Huang and his accompanying team had a preliminary understanding of the strategic positioning of Shenzhen Cell Valley, the uniqueness of its core technology and its future development direction. Subsequently, through the field visit and in-depth investigation of our GMP level production research and development laboratory and quality management system, Director Huang and his delegation had a more profound and comprehensive understanding of the system construction of Shenzhen Cell Valley.
At the symposium, Chairman Shi Yuanyuan elaborated on the core technical advantages of Shenzhen Cell Valley in the field of retrovirus vectors, recent significant scientific research achievements and clinical application cases. Chairman Shi Yuanyuan said that at present, the product pipeline of Shenzhen Cell Valley is showing a booming trend, and the product line is increasingly rich and improving. In the independent research and development project, the company has successfully achieved a number of remarkable breakthroughs such as the innovation of Human NK cell freezing technology and the optimization and upgrading of γδT cells. At the same time, our company has carried out in-depth cooperation with a number of domestic public third class hospitals in the field of CRO projects, and these cooperation projects have made remarkable progress in a number of key areas. In addition, as the executive director of the national biotechnology industry integration Community, we have established a close cooperative relationship with a number of domestic universities, and have a mature oriented talent training system. By building a win-win cooperation model between schools and enterprises, medical enterprises, and government enterprises, resources are shared and advantages are complementary. In recent years, the advantages, investment projects, policy environment and development prospects of the biomedical industry chain in Jingzhou, Hubei Province have attracted much attention. In order to further promote the development of this field, this conference aims to establish a close cooperation model with local hospitals in Jingzhou, jointly build a cell therapy center and a cell preparation center, and promote the innovation and breakthrough of the biomedical industry in the Central region and the Greater Bay Area.
Director Huang Kai gave a high degree of recognition and appreciation to the enterprise construction and core technology of Shenzhen Cell Valley. He said that Jingzhou's economic structure is rich and diversified, covering hundreds of billions of scale equipment manufacturing, light industry construction, agricultural product processing and pharmaceutical and chemical industry and other pillar industries. Especially in the field of medicine, our city has more than ten enterprises above designated size, focusing on the production and research and development of chemical drugs, biological drugs, proprietary Chinese medicines, health materials and medical supplies. Of these companies, eight have obtained drug production licenses, five have passed GMP certification, and two have been identified as high-tech enterprises. At present, Jingzhou has initially built a full chain of biomedical industry development pattern. In this context, Director Huang Kai stressed that cooperation and innovation are the key to promoting the leapfrog development of the biomedical industry. Therefore, this meeting not only focuses on the joint construction with Shenzhen Cell Valley Cell Therapy and Preparation Center, but also looks at a broader field of cooperation, aiming to accelerate the transformation and application of scientific and technological achievements by deepening the cooperation between school enterprises, medical enterprises and government enterprises, and jointly promote the prosperity and development of the biomedical industry.
Both sides believe that by integrating the resources of the two places and complementing each other's advantages, it will effectively promote the innovative development of the biomedical industry and inject new vitality and growth points into the local economy. The two sides are committed to working together to promote innovation and breakthroughs in the field of cell therapy, and make greater contributions to the progress of human health.
